U.S. Multiomics Market (By Product & Service: Instruments, Consumables; By Type: Single-cell, Bulk; By Platform; By Application; By End-use) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

U.S. Multiomics Market Size and Trends

The U.S. multiomics market size was estimated at around USD 1.08 billion in 2023 and is projected to hit around USD 4.59 billion by 2033, growing at a CAGR of 15.58% from 2024 to 2033.

Key Pointers

• By Product & Services, the product segment held the largest revenue share in the market in 2023
• By Product & Services, the service segment is expected to expand at the highest CAGR of 17.65% from 2024 to 2033.
• By Type, the bulk multiomics segment dominated the market in 2023.
• By Type, the single-cell multiomics segment is projected to grow at the fastest compound annual growth rate (CAGR) of 18.18% over the forecast period.
• By Platform, the genomics segment generated the maximum market share of 40% in 2023.
• By Application, the oncology segment captured the maximum market share of 41% in 2023.
• By End-use, the academic and research institutes dominated the segment had the largest market share of 50% in 2023.

U.S. Multiomics Market Overview

The multiomics market in the United States is experiencing significant growth, driven by advancements in technology, increased funding for research, and a rising demand for personalized medicine. The convergence of high-throughput sequencing technologies, bioinformatics, and machine learning is enabling researchers and clinicians to analyze complex biological data sets with greater precision and efficiency.

U.S. Multiomics Market Growth Factors

The growth of the U.S. multiomics market is driven by the technological advancements, increased funding for research, and the rising demand for personalized medicine. Cutting-edge technologies such as next-generation sequencing and mass spectrometry have significantly lowered the costs and enhanced the efficiency of multiomics analyses, making them more accessible. Additionally, substantial investments from government bodies and private organizations are supporting large-scale multiomics projects aimed at understanding complex diseases. The shift towards personalized medicine is also a major driver, as multiomics provides the comprehensive molecular insights needed to develop tailored treatments and improve patient outcomes.

U.S. Multiomics Market Trends:

• Decreasing Costs: Significant reduction in the costs of high-throughput sequencing and mass spectrometry, making multiomics research more feasible and widespread.
• Personalized Medicine: Growing emphasis on personalized medicine, driving demand for multiomics approaches to tailor treatments based on individual molecular profiles.
• Big Data Analytics: Expansion in the use of big data analytics and bioinformatics tools to manage and interpret large, complex multiomics datasets effectively.
• Clinical Applications: Expanding clinical applications of multiomics in diagnostics, biomarker discovery, and therapeutic development, particularly for complex diseases like cancer and neurodegenerative disorders.
• Standardization Efforts: Ongoing efforts to standardize data formats and methodologies in multiomics research to ensure consistency and reliability of data across studies.
• Cloud Computing: Growing adoption of cloud computing solutions to store, share, and analyze multiomics data, facilitating easier access and collaboration.

U.S. Multiomics Market Restraints:

• Data Complexity: The sheer volume and complexity of multiomics data can be overwhelming, posing significant challenges in data integration, analysis, and interpretation.
• High Costs: Despite decreasing costs, high expenses associated with advanced multiomics technologies and data analysis tools can still be a barrier for widespread adoption.
• Technical Expertise: A shortage of skilled professionals with expertise in bioinformatics, data science, and multiomics is limiting the pace of research and development.
• Standardization Issues: Lack of standardized protocols and data formats across different omics platforms complicates data comparison and reproducibility of results.
• Data Privacy and Security: Concerns over data privacy and security, particularly with sensitive genetic information, can hinder data sharing and collaborative research efforts.
• Integration Challenges: Difficulty in integrating multiomics data with existing clinical workflows and electronic health record (EHR) systems can slow down the translation of research findings into clinical practice.

Product & Services Insights

Based on products and services, the product segment held the largest revenue share in the market in 2023. This segment is further divided into instruments, consumables, and software. The growth in this segment is driven by ongoing developments and an increasing number of product launches. Research highlights the efficiency of genomics in predicting and identifying novel compounds, which significantly contributes to drug development and synthetic biology. For instance, in March 2023, Mission Bio partnered with CMaT to enhance cell therapy development using the Tapestri Platform, addressing manufacturing challenges to ensure the safe and rapid delivery of potentially life-saving therapies.

The service segment is expected to register the fastest compound annual growth rate (CAGR) of 17.65% over the forecast period. This segment is experiencing significant growth due to the rising demand for specialized expertise and comprehensive solutions. Services in this segment include experimental design, sample preparation, data generation, and in-depth bioinformatics analysis, all of which are crucial for helping researchers and organizations navigate multiomics workflows and achieve accurate results.

Type Insights

Based on type, the market is segmented into single-cell multiomics and bulk multiomics. The bulk multiomics segment dominated the market in 2023. This segment is essential for providing a comprehensive understanding of the pathogenesis of disorders and diverse phenotypes at the individual level. Its dominance is due to several advantages, including a straightforward experimental process and cost-effective analysis of large-scale samples. Additionally, the bulk multiomics method eliminates the need for living cells.

The single-cell multiomics segment is projected to grow at the fastest compound annual growth rate (CAGR) of 18.18% over the forecast period. An article published by Nature Reviews Molecular Cell Biology in April 2023 highlights recent progress in single-cell analyses and barcoding strategies, emphasizing innovative techniques that integrate genome, epigenome, and transcriptome profiling. These advancements provide better specificity, precision, and resolution, leading to a deeper understanding of cellular heterogeneity, differentiation, and epigenetic reprogramming, thereby driving the growth of this segment over the forecast period.

Platform Insights

Based on platform, the market is segmented into genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms. The genomics segment dominated the market in 2023 with a revenue share of 40%. This dominance is driven by advancements such as CRISPR/Cas9 genome editing. Diverse data streams, including wearables and clinical data, are enabling a holistic approach to personalized medicine. Furthermore, in December 2023, the FDA approved the first CRISPR gene-editing treatment, exa-cel, for sickle cell disease. Developed by Vertex and CRISPR Therapeutics, this approval reinforces the integration of genomics into clinical practice, paving the way for increased adoption of gene-editing techniques in healthcare. These factors are anticipated to boost the growth of the genomics segment over the forecast period.

The metabolomics segment is expected to grow at the fastest compound annual growth rate (CAGR) over the forecast period. This platform is a promising technology integral to precision medicine, involving the comprehensive analysis of metabolites within a biological specimen. Modern metabolomic technologies surpass the scope of small-scale metabolite detection, enabling the precise analysis of hundreds to thousands of metabolites. This capability is expected to drive the growth of the metabolomics segment over the forecast period.

Application Insights

The market is segmented based on application into cell biology, oncology, neurology, and bulk immunology. The oncology segment dominated the market in 2023, holding a market share of 41%, and is projected to experience the fastest compound annual growth rate (CAGR) over the forecast period. This dominance is attributed to the increasing need to comprehend complex molecular interactions in cancer development. Moreover, strategic investments by key market players in cancer research are significant growth drivers. For example, in June 2023, collaborative efforts between Owkin, NanoString, and renowned cancer research institutions led to the launch of MOSAIC—a groundbreaking USD 50 million spatial omics project with the potential to redefine cancer research.

The neurology segment is expected to grow at a substantial CAGR over the forecast period. Multiomics technologies have profoundly impacted neurology, revolutionizing the understanding of complex neurological disorders. Next-generation sequencing, transcriptomics, proteomics, and metabolomics have become indispensable tools, facilitating the unbiased identification of disease-causing gene variants and biomarkers. These factors are anticipated to propel the growth of the neurology segment over the forecast period

End-use Insights

The market is segmented by end-use into academic and research institutes, pharmaceutical and biotechnology companies, and others. Academic and research institutes dominated the segment, holding a market share of 50% in 2023. Numerous government organizations, such as the NIH, provide funding to specific multiomics sequencing and analysis centers dedicated to understanding the genomic bases of rare and common human diseases. The Centers for Common Disease Genomics, a division of the NIH, utilize genome sequencing to investigate and ascertain the influence of omics on prevalent diseases like autism, stroke, diabetes, and heart diseases. For example, in September 2023, the NIH granted USD 50.3 million for multiomics research on various human diseases and health.

The pharmaceutical and biotechnology companies segment is projected to achieve the fastest compound annual growth rate (CAGR) over the forecast period. Next-generation sequencing (NGS) is rapidly gaining importance in biopharmaceutical manufacturing processes. Advanced technology is enhancing the development of cell lines and quality assurance practices. Moreover, these sequencing techniques guide the development of medications for targeted therapy and precision medicine. For instance, NGS enables researchers to discover and characterize new molecular targets, including targets that could aid in the development of therapies for diseases previously deemed incurable. Therefore, the adoption of such advanced technology is expected to drive the growth of the segment from 2024 to 2033.

U.S. Multiomics Market Key Companies

• BD
• Thermo Fisher Scientific, Inc.
• Illumina, Inc
• Danaher (Beckman Coulter)
• PerkinElmer, Inc
• Shimadzu Corporation
• Bruker
• QIAGEN
• Agilent Technologies, Inc.
• BGI Genomics

Recent Developments

• In January 2023, Agilent Technologies, Inc. announced the acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers using NGS methods to study cancers.
• In February 2023, BD introduced the BD Rhapsody HT Xpress System to assist scientists in conducting high-throughput studies without compromising the integrity of their samples.
• In September 2023, Bruker introduced the novel 4D-Proteomics timsTOF, which offers precise quantification of peptides and proteins within hundreds or thousands of samples by employing global retention time and Collision Cross-Section (CCS) prediction models.

U.S. Multiomics Market Segmentation:

By Product & Services

• Products
  • Instruments
  • Consumables
  • Software
• Services

By Type

• Single-cell Multiomics
• Bulk Multiomics

By Platform

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics
• Integrated Omics Platforms

By Application

• Cell Biology
• Oncology
• Neurology
• Immunology

By End-use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others